Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 14/20 | 0.44 |
| ▸ | KDR | P35968 | 11/20 | 0.44 |
| ▸ | TEK | Q02763 | 2/20 | 0.40 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.39 |
| ▸ | RET | P07949 | 2/20 | 0.39 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.39 |
| ▸ | CDK8 | P49336 | 2/20 | 0.39 |
| ▸ | NTRK3 | Q16288 | 2/20 | 0.39 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.39 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.39 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.39 |
| ▸ | LTK | P29376 | 1/20 | 0.39 |
| ▸ | FLT3 | P36888 | 1/20 | 0.39 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5899326 | 0.89 | CA12 (0.46) | BRAFKDRTEKPDGFRB | |
| SCHEMBL5899284 | 0.85 | KDR (0.44) | BRAFKDRTEKNTRK1RET | |
| SCHEMBL5899288 | 0.83 | KDR (0.47) | BRAFKDRTEKNTRK1RET | |
| SCHEMBL5899310 | 0.83 | KDR (0.51) | BRAFKDRTEKRETPDGFRB | |
| SCHEMBL5899271 | 0.71 | CDK8 (0.49) | BRAFKDRPDGFRBCDK8MAPK14 | |
| SCHEMBL5899285 | 0.70 | KDR (0.54) | BRAFKDRTEK | |
| SCHEMBL5899280 | 0.66 | KDR (0.44) | BRAFKDRTEK | |
| SCHEMBL15925265 | 0.64 | CA12 (0.55) | BRAFKDRNTRK1RETPDGFRB | |
| SCHEMBL59556 | 0.62 | CA12 (0.56) | BRAFKDRNTRK1RETPDGFRB | |
| SCHEMBL3844571 | 0.62 | KDR (0.47) | BRAFKDRTEKNTRK1RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | claimed |
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | MERCK PATENT GMBH (DE) | 2006-10-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241301-A1 | Urea derivatives and their use as tyrosinkinase inhibitors | TIE1, UCK2, UTS2R | BRAF 34/4885KDR 45/4885TEK 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.